Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta
Trelegy Ellipta is a product in which
Trelegy Ellipta is the first treatment to provide a combination of three molecules in a single inhaler that only needs to be taken once a day. The unique combination treatment includes: FF, an inhaled corticosteroid; UMEC, a long-acting muscarinic antagonist (LAMA); and VI, a long-acting beta2-adrenergic agonist (LABA). This combination has been formulated to be delivered once-daily in GSK's simple-to-use delivery device, the ELLIPTA® dry powder inhaler.
In a press release dated
Trelegy Ellipta was approved in
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the US,
In addition, we have an economic interest in future payments that may be made by
For more information, please visit www.theravance.com.
THERAVANCE®, the Cross/Star logo, and VIBATIV® are registered trademarks of the
This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events.
Head of Investor Relations
View original content with multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-highlights-submission-of-landmark-impact-data-to-ema-to-support-expanded-label-for-trelegy-ellipta-300599122.html